Versantis’ VS-02 is a pre-clinical oral, small molecule drug candidate being developed for the chronic management of HE (hepatic encephalopathy), considered an endemic disease worldwide.
Versantis has raised €500k across 1 funding round from 4 investors, most recently a round in Apr 2025. Based in Zurich, Switzerland; active in Healthtech. Acquired by GENFIT in 2022. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-04-18 | Other | €500k | a French impact fund,Antler,Business Angels,Climate Leaders Fast Track | View deal → |
